GSK3640254 + dolutegravir

GSK3640254 + dolutegravir is an investigational, orally available fixed-dose combination regimen for the treatment of HIV-1 infection. GSK3640254 is a novel HIV-1 maturation inhibitor that interferes with the final step in the viral life cycle, preventing proper maturation of new virions and thus inhibiting their infectivity[5][3]. Dolutegravir is an integrase strand transfer inhibitor that blocks the integration of viral DNA into the host genome, a critical step in HIV replication[8][6][4]. The combination aims to provide a two-drug regimen with complementary mechanisms of action for people living with HIV. Clinical studies have shown that coadministration does not result in clinically significant drug interactions and is well tolerated[1][3]. The primary indication under investigation is treatment of human immunodeficiency virus (HIV) infection.

Brand names

Tivicay